Accessibility Menu
Fresenius SE & Co logo

Fresenius SE & Co(OTC) FSNUY

Market Cap$29.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2011)+105%
5 Year+12%
1 Year-1%
1 Month+2%
$13.02
-1.32%
-0.17Today
Fresenius SE & Co last closing stock price
MetricPriceDate
Last closeUSD 13.192026-08-31
Fresenius SE & Co stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-2.08%USD 13.472026-08-24
1 month+2.41%USD 12.882026-07-31
3 month+23.78%USD 10.662026-06-02
Year to date-5.42%USD 13.952025-12-31
1 year-0.76%USD 13.292025-08-29
3 year+74.1%USD 7.582023-09-01
5 year+12.44%USD 11.732021-09-01
Since inception+105.4%USD 6.422011-12-12

Fresenius SE & Co Financials at a Glance

Market Cap

$29.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

€23.53B

Net Income (TTM)

€1.53B

EPS (TTM)

$0.79

P/E Ratio

16.74

Dividend

$0.30

Beta (Volatility)

0.55 (Low)

Price

$13.02

Volume

17,475

Open

$13.21

Previous Close

$13.19

Daily Range

$12.95 - $13.25

52-Week Range

$10.33 - $33.93

Estimated Earnings Date

Nov 4, 2026

FSNUY News

No articles available.

Motley Fool Moneyball Superscore

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Fresenius SE & Co

Fresenius SE & Co. KGaA is a leading healthcare group specializing in products and services for dialysis, hospitals, and outpatient medical care. The company operates through four segments: Fresenius Medical Care, Fresenius Kabi, Fresenius Helios, and Fresenius Vamed, providing comprehensive healthcare solutions globally.

Products and Services
  • Fresenius Medical Care focuses on renal disease treatment and dialysis services
  • Fresenius Kabi offers lifesaving medicines and medical technologies
  • Fresenius Helios provides inpatient and outpatient care, including telemedicine
Growth Outlook
  • Revenue growth of 2.5% year-over-year in Q2 2026
  • Strong demand for dialysis services supports long-term growth
  • Expansion in telemedicine enhances service delivery and patient access
Financial Highlights
  • Q2 2026 net income of €388 million, reflecting a 10% increase from Q1 2026
  • Trailing twelve months (TTM) revenue of €24.1 billion, indicating stable performance
  • Dividend yield of 2.29%, appealing for income-focused investors
Fresenius SE & Co. KGaA has established itself as a key player in the healthcare sector, with a diversified portfolio that addresses critical medical needs. The company's focus on innovation and expansion in various healthcare segments positions it well for future growth. Recent financial performance demonstrates resilience, with consistent revenue generation and profitability. The commitment to enhancing patient care through advanced technologies and services further solidifies its market presence. Investors may find the company's stable dividend yield and growth potential attractive in the evolving healthcare landscape.
AI Generated • Aug 29, 2026

Industry

Healthcare Providers and Services

Sector

Health Care

Employees

178,486

CEO

Michael Sen, MBA

Website

www.fresenius.de

Headquarters

Bad Homburg vor der Höhe, HE 61352, DE

FSNUY Financials

Key Financial Metrics (TTM)

Gross Margin

25.25%

Operating Margin

9.60%

Net Income Margin

6.50%

Return on Equity

7.89%

Return on Capital

6.74%

Return on Assets

3.64%

Earnings Yield

5.97%

Dividend Yield

2.31%

Payout Ratio

46.78%

Stock Overview

Market Cap

$29.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

2.25B

Volume

17.48K

Avg. Volume

222.58K

Financials (TTM)

Gross Profit

€5.94B

Operating Income

€2.26B

EBITDA

€3.42B

Operating Cash Flow

€2.93B

Capital Expenditure

-€1.51B

Free Cash Flow

€1.42B

Cash & ST Invst.

€1.28B

Total Debt

€11.41B

Fresenius SE & Co Performance Analysis

Fresenius SE & Co annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31EUR 22,416,231,199-48.8%
20232023-12-31EUR 22,775,862,4081.6%
20242024-12-31EUR 23,747,438,8644.3%
20252025-12-31EUR 25,813,963,4648.7%
Fresenius SE & Co sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-30-2.0%
Q42025-12-3111.4%
Q12026-03-31-3.0%
Q22026-06-302.2%
Fresenius SE & Co annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31EUR 0.64-33.3%
20232023-12-31EUR -0.29N/A
20242024-12-31EUR 0.23N/A
20252025-12-31EUR 0.63180.1%
Fresenius SE & Co sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q32025-09-307.1%
Q42025-12-316.7%
Q12026-03-3125.0%
Q22026-06-30-15.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q2 2026YOY CHG

Revenue

€6.04B

+8.3%

Gross Profit

€1.58B

+8.1%

Gross Margin

26.07%

N/A

Market Cap

$29.72BMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$166.58K

N/A

Employees

178,394

N/A

Net Income

€388.32M

+17.7%

EBITDA

€896.60M

+8.3%

Quarterly Fundamentals

Name
Q2 2026YOY CHG

Total Cash

€1.28B

-8.1%

Total Debt

€11.41B

-11.2%

Accounts Receivable

€6.22B

+19.4%

Inventory

€2.77B

+6.9%

Long Term Debt

€9.55B

-9.9%

Short Term Debt

€1.86B

-17.5%

Return on Assets

3.64%

N/A

Return on Invested Capital

6.86%

N/A

Free Cash Flow

€208.45M

+0.7%

Operating Cash Flow

€467.97M

+12.0%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
SMMNYSiemens Healthineers AG
$22.64-0.20%
FMCQFFresenius Medical Care AG
$51.44+0.00%
ESLOYEssilorLuxottica S.A.
$92.45-0.41%
ESLOFEssilorLuxottica S.A.
$185.54+0.81%

Trending Stocks

Symbol / CompanyPricePrice Chg
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x ETF
$9.46-0.05%
NVDANvidia
$219.31-0.01%
BIAFbioAffinity Technologies
$6.70+0.47%
INTCIntel
$89.07-0.00%

Questions About FSNUY

What is the current price of Fresenius SE & Co?

Fresenius SE & Co is trading at $13.02 per share.

What is the 52-week range for Fresenius SE & Co?

Over the past 52 weeks, Fresenius SE & Co has traded between $10.33 and $33.93.

How much debt does Fresenius SE & Co have?

As of the most recent reporting period, Fresenius SE & Co reported total debt of €13.05B.

How much cash does Fresenius SE & Co have on hand?

Fresenius SE & Co reported €1.46B in cash and cash equivalents in its most recent financial results.

What is Fresenius SE & Co’s dividend yield?

Fresenius SE & Co currently has a dividend yield of 2.31%.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services